2020
DOI: 10.12659/ajcr.919701
|View full text |Cite
|
Sign up to set email alerts
|

Post-Renal Biopsy Acute Kidney Injury and Page Kidney from Intra-Renal Hematoma Aggravated by Reversible Contrast-Induced Nephropathy Following Renal Arterial Embolization

Abstract: rial hypertension from "cellophane perinephritis". By 2009, about 100 cases of Page kidney had been reported. Bleeding complications after percutaneous kidney biopsy has, however, been well described. Moreover, the perioperative management of the recently introduced non-vitamin K antagonist anticoagulants (NOACs) remains uncertain due to inadequate evidence. Current guidelines to determine the appropriate duration of withholding NOACs before a surgical procedure, and when to restart NOACs safely after a proced… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 28 publications
0
1
0
1
Order By: Relevance
“…In addition, the iodine contrast agent used in angiography has shortcomings such as allergic reactions and acute kidney injury. After embolization there might be complications such as postembolization syndrome, infection, and renal insufficiency ( Dinkel et al, 2002 ; Onuigbo et al, 2020 ; Sayani et al, 2012 ). Postembolization syndrome, which is the most common complication, can affect up to 90% of patients ( Ginat et al, 2009 ).…”
Section: Introductionmentioning
confidence: 99%
“…In addition, the iodine contrast agent used in angiography has shortcomings such as allergic reactions and acute kidney injury. After embolization there might be complications such as postembolization syndrome, infection, and renal insufficiency ( Dinkel et al, 2002 ; Onuigbo et al, 2020 ; Sayani et al, 2012 ). Postembolization syndrome, which is the most common complication, can affect up to 90% of patients ( Ginat et al, 2009 ).…”
Section: Introductionmentioning
confidence: 99%
“…Die angegebene Empfehlung zum Absetzen und Wiederbeginn des NOAK sind abhängig vom Grad der Niereninsuffizienz, des NOAK-Präparats und der Begleitmedikation[44]. Aufgrund schwerwiegender Blutungskomplikationen in einem Fallbericht[45] und eigenen Erfahrungen empfehlen die Autoren im Einzelfall unter Abwägen des Thrombembolie-und Blutungsrisikos das NOAK erst ≥ 7 Tage nach der Biopsie wieder zu beginnen.…”
unclassified